cDNA Cloning of a Vacuolar H^+-Pyrophosphatase and Its Expression in Hordeum brevisubulatum (Trin.) Link in Response to Salt Stress

A cDNA clone encoding a vacuolar H+-pyrophosphatase (V-H+-PPase) was isolated from Hordeum brevisubulatum (Trin.) Link by using RACE method. Sequence analysis revealed that HbVP1 contained 2 319 nucleotides of open reading frame (ORF) and 420 nucleotides of 3′-untranslated region. Its encoding protein consisted of 773 amino acid residues, which includes 14 transmembrane helices. The predicated molecular mass is 80.4 kDa with pI of 4.90. The V-H+-PPases in higher plants shared low identity (40-55%) with those of protozoa, marine alga and archaebacteria. HbVP1 transcripts accumulated abundantly in roots, shoots and seeds, and it was also strongly induced by salt treatment.

国产吲达帕胺应用于高血压的安全性及其影响因素

目的评价国产吲达帕胺的安全性及影响因素。方法利用一项正在进行的多中心随机对照试验2019年9月至2021年12月期间的随访数据开展前瞻性队列研究。分析吲达帕胺使用1~3个月期间不良事件的发生情况。利用广义估计方程模型,探究用药情况及个体因素对其发生风险的影响。结果研究共纳入含吲达帕胺的处方12722例次,来源于2312例具有心血管疾病高危风险的高血压患者。所有处方对应患者平均年龄(65.3±7.0)岁,58.0%为男性。所有处方中5.60%发生了不良事件;其中定期监测发现的低钾血症(3.93%)和低钠血症(1.37%)最常见。中重度低钾血症和中重度低钠血症发生率分别为0.31%和0.16%。在不停药情况下,65.8%低钾血症和72.5%低钠血症可恢复正常。处方前患者血钾3.5~3.9 mmol/L(RR=2.11,95%CI:1.82~2.43)、血钠135~139 mmol/L(RR=1.21,95%CI:1.05~1.40)、吲达帕胺剂量≥2.5 mg(RR=1.37,95%CI:1.07~1.75)与发生不良事件风险升高相关。联合用药是提高吲达帕胺安全性的保护因素。结论国产吲达帕胺安全性好。定期监测血钾、血钠,尤其关注血钾、血钠处于正常低值者,采用小剂量联合用药策略可改善吲达帕胺安全性。